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A Long-Acting Ring for Women’s HIV Prevention
The monthly dapivirine ring, developed by the nonproﬁt International Partnership for Microbicides, adapts a
medical technology commonly used to deliver hormones to women—a vaginal ring—to the eﬀort against HIV.

Despite progress against HIV/AIDS, women continue to face persistently
high infection rates, particularly in sub-Saharan Africa. Women urgently
need new prevention choices that meet their varied needs, which can
change throughout their lives.

Oﬀering Women Hope
IPM’s monthly dapivirine ring could fill an important gap with a longacting prevention method for women who are unable or choose not
to use higher-efficacy products like daily oral PrEP.

Regulatory Status
The dapivirine ring received a positive scientific opinion in 2020 from
the European Medicines Agency (EMA) for use among women ages 18
and older in developing countries. The product was also prequalified by
the World Health Organization (WHO) in 2020, and in 2021 received a
WHO recommendation and was included in WHO’s HIV guidelines.
IPM is seeking regulatory approvals in eastern and southern Africa, with
approval received in Zimbabwe and several other countries in the region
in 2021 and additional reviews underway. IPM has been working across
sectors to prepare for the ring’s possible introduction.

Dapivirine Ring Research: Efficacy, Safety, Acceptability
Efficacy: Two Phase III studies found that the dapivirine ring reduced
women’s risk of HIV-1 infection by about 30% with no safety concerns
with long-term use.


The Ring Study, led by IPM, found that the ring reduced overall risk
by 35%, and ASPIRE, led by the US National Institutes of Healthfunded Microbicide Trials Network (MTN), found that the ring
reduced overall risk by 27%.



Together, the two studies evaluated monthly use of the ring in
nearly 4,600 women ages 18-45 in Malawi, South Africa, Uganda
and Zimbabwe.

A Product of Partnership
IPM pioneered the ring’s development
through public-private partnerships
that brought scientific ingenuity,
political will and financial resources
to bear at every phase of product
development.
IPM obtained a royalty-free license
from the Janssen Pharmaceutical
Companies of Johnson & Johnson
in 2004 to develop dapivirine as a
microbicide for women. That license
expanded in 2014 to an exclusive
worldwide rights agreement that
ensures any dapivirine product will
be made available at low cost in
resource-limited settings.
IPM took the ring from concept to
regulatory reviews in cooperation
with governments, foundations,
researchers, industry, advocates and
communities. It will require that same
level of collaboration to finance and
coordinate the ring’s introduction,
where it is approved for use.

OLE results: Two subsequent open-label extension (OLE) studies,
DREAM and HOPE, showed increased ring use compared to the Phase
IIIs, and modeling data suggested greater risk reduction—by over 50%
across both OLEs.
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IPM is a nonprofit organization dedicated to developing new HIV prevention technologies for
women and making them available in developing countries where the epidemic has hit hardest.
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From Concept to Results—
and Beyond

2004

IPM obtains dapivirine
license and begins
preclinical work

2005–
2010

IPM develops ring,
tests four prototypes
and advances one to
additional clinical trials

2010–
2012

Four early-stage studies
show the ring has a strong
safety profile and is
acceptable to women

2012

Two Phase III studies
launch in Africa

2016

Phase III studies show
the dapivirine ring reduced
women’s HIV risk with no
safety concerns

2017

First regulatory submission,
ongoing research and
preparations for ring rollout

2019

Two OLE studies show
increased ring use and
suggest greater HIV risk
reduction compared to
Phase III studies

2020

Monthly dapivirine
ring receives positive
EMA opinion and
WHO prequalification

2021

WHO recommends
dapivirine ring for women
at substantial HIV risk
First country approval
received

Safety: In addition to the Phase III and OLE studies, over 40 safety
studies of different dapivirine formulations (oral treatment, gel, film
and ring) support the ring’s strong safety profile.
Acceptability: Nearly all women in two IPM acceptability studies in
Africa found the ring to be acceptable and expressed interest in using
it if proven effective. Many women in the Phase III studies reported
forgetting the ring was in place and that neither they nor their partner
could feel it during sex.
Key groups: A safety study of the ring is ongoing in Africa by the MTN
among adolescent girls and young women (REACH), which may support
future regulatory approvals. IPM is planning additional research to
better understand the ring’s efficacy among women ages 18-25. MTN
is also conducting safety studies among pregnant women (DELIVER)
and breastfeeding women (B-PROTECTED), both in Africa, to help us
understand how the ring could fit into the lives of these key groups.

Potential Public Health Impact
Expanding women’s options so they can choose the method that best
meets their individual needs is essential to controlling the HIV/AIDS
epidemic. Modeling studies show that a combination approach is
needed to end the epidemic—and that microbicides like the dapivirine
ring could have a meaningful impact as part of a portfolio that includes
condoms, PrEP and TasP, vaginal rings, future long-acting injectables,
and implants and vaccines in development.

Long-acting and Woman-controlled
The dapivirine ring marks the first time a vaginal ring has been shown
to deliver an ARV for HIV prevention. Where approved, the ring would
offer women the first long-acting tool they can control themselves and
use discreetly to reduce their HIV risk.

Ring Technology: Slow-release and Locally-acting
Vaginal rings provide controlled release of drugs over extended time
periods. IPM’s ring is a novel formulation made of flexible silicone with
25mg of the ARV dapivirine dispersed uniformly in its matrix (56mm
outer diameter, 7.7mm cross-sectional diameter). The ring slowly
delivers the drug directly to the site of potential infection over a month,
with low systemic exposure, which could help minimize side effects.

Active Ingredient: Dapivirine
Dapivirine belongs to the same class of ARVs used to successfully
treat HIV/AIDS and prevent vertical transmission. Known as a nonnucleoside reverse transcriptase inhibitor, it works by blocking HIV
from replicating inside a healthy cell.

Follow-on Products: Building on the Monthly Ring
IPM is also developing longer-acting rings that could reduce annual
costs, including a three-month dapivirine ring, and a three-month
ring designed to prevent both HIV and unintended pregnancy.

